Zaloguj Zarejestruj się zadarmo

Inhibrx organizacji EV/EBITDA

Jaka jest wartość EV/EBITDA organizacji Inhibrx?

Wartość EV/EBITDA organizacji Inhibrx, Inc. to N/A

Jaka jest definicja EV/EBITDA?



EV / EBITDA to wartość przedsiębiorstwa podzielona przez zyski przed odsetkami, podatkami, amortyzacją i amortyzacją. Jest to miara tego, jak cenny jest czas i jest częściej stosowany w przypadku porównań między przedsiębiorstwami niż stosunek ceny do zarobku. Mierzy on cenę (w postaci wartości przedsiębiorstwa), którą inwestor płaci na rzecz przepływów pieniężnych firmy (w postaci EBITDA).

Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.

EV/EBITDA firm w Health Care sektor na NASDAQ w porównaniu do Inhibrx

Czym się zajmuję organizacja Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Firmy z ev/ebitda podobne do Inhibrx